Krystal Biotech Reports 24% Revenue Growth to $119.2 Million in Latest Quarter

Krystal Biotech, Inc. reported significant financial growth in its latest quarterly results, with product revenue reaching $119.2 million for the three months ended June 30, 2026, a 24% increase from $96.0 million in the same period last year. For the six months ending June 30, 2026, the company generated $235.6 million in product revenue, up 28% from $184.2 million in the prior year. The increase in revenue is primarily attributed to the successful launch of its gene therapy product, VYJUVEK, in European and Japanese markets, despite a decline in sales within the United States.

Operating expenses for the second quarter of 2026 totaled $60.8 million, a 7% increase from $56.6 million in the previous year. This rise was driven by a 14% increase in selling, general, and administrative expenses, which amounted to $39.9 million, reflecting higher payroll and marketing costs associated with VYJUVEK's commercialization. Research and development expenses remained relatively stable, increasing slightly to $14.5 million from $14.4 million. The company reported a net income of $54.8 million for the quarter, a 43% increase compared to $38.3 million in the same quarter of 2025.

In terms of operational metrics, Krystal Biotech's cash and cash equivalents stood at $427.7 million as of June 30, 2026, down from $496.3 million at the end of 2025. The company also reported a total of $1.5 billion in assets, up from $1.3 billion at the end of the previous fiscal year. The increase in total assets was driven by a rise in short-term investments and accounts receivable, which reached $138.7 million, reflecting the growing demand for VYJUVEK. The company’s employee headcount has also increased, supporting its expanding operations and commercialization efforts.

Strategically, Krystal Biotech is focused on expanding its market presence and product offerings. The company is actively pursuing pricing negotiations in Germany and France, with plans to submit additional marketing authorization applications for VYJUVEK in Switzerland and Australia in the second half of 2026. Furthermore, Krystal is advancing its pipeline of product candidates, including KB803 for ocular complications related to dystrophic epidermolysis bullosa and KB407 for cystic fibrosis, with ongoing clinical trials expected to yield results later this year.

Looking ahead, Krystal Biotech anticipates continued revenue fluctuations due to the timing of product sales and ongoing commercialization efforts. The company believes its current cash reserves and short-term investments will be sufficient to fund operations for at least the next 12 months. However, it acknowledges the potential need for additional capital to support its growth strategy, including further clinical trials and product launches. The management remains optimistic about the future, citing the strong market demand for VYJUVEK and the promising developments in its product pipeline.